ATARA Biotherapeutics (ATRA) Misses Q2 EPS by 2c

ATARA Biotherapeutics (NASDAQ: ATRA) reported Q2 EPS of ($0.68), $0.02 worse than the analyst estimate of ($0.66). Revenue for the quarter came in at $960 thousand versus the consensus estimate of $4.36 million.

For earnings history and earnings-related data on ATARA Biotherapeutics (ATRA) click here.

You May Also Be Interested In

• BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
• Forum Markets, Incorporated (FRMM) Tops Q2 EPS by 29c ; Offers Guidance
• McGraw Hill (MH) Tops Q2 EPS by 11c, Beats on Revenue; Offers FY26 Guidance